Cargando…
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Therapeutic strategies aiming at mobilizing immune effector cells to kill tumor cells independent of tumor mutational load and MHC expression status are expected to benefit cancer patients. Recently, we engineered various peptide-Fc fusion proteins for directing Fcg receptor-bearing immune cells tow...
Autores principales: | Mobergslien, Anne, Peng, Qian, Vasovic, Vlada, Sioud, Mouldy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342789/ https://www.ncbi.nlm.nih.gov/pubmed/27713158 http://dx.doi.org/10.18632/oncotarget.12445 |
Ejemplares similares
-
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
por: Sioud, Mouldy, et al.
Publicado: (2015) -
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
por: Sioud, Mouldy, et al.
Publicado: (2016) -
Structural Requirements for the Binding of a Peptide to Prohibitins on the Cell Surface of Monocytes/Macrophages
por: Zhang, Qindong, et al.
Publicado: (2022) -
Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells
por: Sioud, Mouldy, et al.
Publicado: (2023) -
Precision Killing of M2 Macrophages with Phage-Displayed Peptide-Photosensitizer Conjugates
por: Sioud, Mouldy, et al.
Publicado: (2023)